

1 **First report of New Clonal groups ST706 and ST1088 from MDR**

2 ***Klebsiella pneumoniae* Mexican strains**

3 **María Guadalupe Córdova-Espinoza^{a,c#}, Eder Daniel Hernández Arana^a, Silvia**
4 **Giono-Cerezo^a, Erika Gabriela Sierra Atanacio^b, Eduardo Carrillo Tapia^d, Laura**
5 **Isabel Carrillo Vázquez^d, Rosa González-Vázquez^{a,b#}.**

6 ^a Departamento de Microbiología. Escuela Nacional de Ciencias Biológicas, Instituto
7 Politécnico Nacional. Plan de Ayala y Carpio. CP11340, CDMX, México.

8 ^b Instituto Mexicano del Seguro Social. Hospital de Especialidades. Centro Médico
9 Nacional. La Raza, Seris y Saachila, SN, Col. La Raza, CP 6450, CDMX, México.

10 ^c Laboratorio Multidisciplinario de Investigación de la Escuela Militar de Graduados de
11 Sanidad SEDENA. Batalla de Celaya 202, Lomas de Sotelo, 11200 Miguel Hidalgo,
12 CDMX, México.

13 ^dUACM, Universidad Autónoma de la Ciudad de México. Posgrado en Ciencias
14 Genómicas. Calle Prolongación San Isidro No. 151, Col. San Lorenzo Tezonco. Iztapalapa,
15 CDMX.

16 Corresponding authors:

17 PhD. Rosa González Vázquez

18 #Instituto Mexicano del Seguro Social. Hospital General. Centro Médico Nacional. La
19 Raza. Seris y Saachila, SN, Col. La Raza, CP 6450, CDMX, México. Rosa González
20 Vázquez, rosagonzvazq@yahoo.com

21 PhD. María Guadalupe Córdova Espinoza

22 # Departamento de Microbiología. Laboratorio de Bacteriología Médica. Escuela Nacional
23 de Ciencias Biológicas, Instituto Politécnico Nacional, Plan de Ayala y Carpio CP11340,
24 CDMX, México. mixtlipp@yahoo.com.mx

25

26 **Abstract**

27 Multidrug-resistant *Klebsiella pneumoniae* Mexican strains were characterized for the
28 identification of endemic and pandemic clonal groups. The aims of this study were to know
29 population structure and to identify endemic clonal groups inside *K. pneumoniae* Mexican
30 strains isolated from clinical sources. We studied 93 isolated strains from three third level
31 hospitals and one family clinic from Mexico City. Identification of the strains was done by
32 conventional microbiological methods and an automated system (Vitek2®). The multidrug-
33 resistant phenotype was confirmed following CLSI recommendations, and the strains were
34 classified as MDR, XDR and PDR. Molecular characterization was done by Multilocus
35 Sequence Typing scheme (*rpoB*, *gapA*, *mdh*, *pgi*, *phoE*, *infB*, y *tonB*). All strains were
36 isolated from hospitalized patients, the most frequent sources were urine and blood
37 cultures. Population structure of *K. pneumoniae* was clonal, 30 ST were identified, six of
38 them are commonly found. The Clonal complex ST25, ST36, S5392, ST405 and ST551
39 were isolated from clinical sources, ST1088 was isolated from surfaces of hospital
40 environment.

41 **Introduction**

42 *Klebsiella pneumoniae* is an opportunist, emerging microorganism, it is an ESKAPE group
43 member (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*,
44 *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and *Enterobacter* species). Also, it is
45 responsible of Healthcare Associated Infection (HCAI) (Central Line-associated
46 Bloodstream Infection, Surgical Site Infection, Catheter-associated Urinary Tract
47 Infections, Ventilator-associated Pneumonia) frequently isolated from immunosuppressed

48 patients from intensive care unit (ICU). *K. pneumoniae* is also related to community-
49 associated infections. The most important virulence factors, which allows it to evade the
50 immune response and promote the microorganism's establishment are: adhesines
51 (fimbriae), capsular polysaccharides (serotypes K1 and K2), siderophores and LPS. (1, 2).

52 *Klebsiella pneumoniae* is frequently identified as a responsible of nosocomial infections.
53 Worldwide, bacterial resistance is an increasing serious problem, as well as extended
54 spectrum beta-lactamases dissemination and different subgroups of CTX-M, which
55 generates cephalosporins resistance, and transferable resistance mechanisms to quinolones
56 and aminoglycosides. The importance of carbapenems transference in plasmids is that they
57 can be transmitted to other bacteria (enterobacteria and other non-fermentative bacilli), as
58 well as the association of resistance to other type of antibiotics. Recent isolation of *K.*
59 *pneumoniae* KPC (resistance to all beta-lactams, cephalosporins, penicillin and
60 monobactams) at ICU from all over the world is associated to the resistance to other
61 antimicrobial agents, which is contained in the same plasmid (3).

62 MDR *K. pneumoniae* laboratory identification is done by conventional microbiological
63 methods. Moreover, it's essential to investigate global dispersion, hospital outbreaks and
64 lineage relationships between resistant strains from hospital and community environment,
65 thus, to compare endemic and pandemic clones through molecular typing methods, like
66 Multilocus sequence typing (MLST).

67 *K. pneumoniae* genetic diversity has been studied previously (4) and it was elucidated that
68 the most dominant ST was from China, other reports show nosocomial clones like ST258,
69 which acquires resistance plasmids with great easiness (5). ST405 is a recently reported

70 clone, which, due to its fast dissemination, is classified as a high-risk clone. The main
71 purpose of this study was to recognize MDR *K. pneumoniae* clones and their prevalence in
72 some Mexican third level healthcare hospitals using MLST technique.

73 Our results showed that there are clones that were previously reported in distant countries
74 to Mexico. Besides, this paper reports two clones that have not been reported yet. These
75 clones are ST706 and ST1088.

76 **Materials and Methods:**

77 ***K. pneumoniae* strains identification and susceptibility test**

78 93 clinical strains from 2011 to 2013, and 2015 were isolated from different third level
79 healthcare hospital units (hospital I, II, III and IV) from Mexico City. Clinical strains were
80 classified in groups: A, which included outpatient.; I, which was formed by hospitalized
81 patients; and S: inert hospital surfaces isolations. Strains were conserved at 70°C.

82 *K. pneumoniae* ATCC 700603 and *E. coli* ATCC 25922 were used as controls for the
83 ESBL test (CLSI, 2018) and molecular methods. All isolated clones were identified, and
84 their antimicrobial susceptibilities were analyzed by an automatized system (Vitek2®
85 BioMerieux®, France).

86 Tested antibiotics were: Ampicillin (AMP), cefazolin (CFZ),
87 trimethoprim/sulfamethoxazole (SXT), ampicillin/sulbactam (SAM), cefepime (FEP),
88 ceftriaxone (CRO), aztreonam (ATM), tobramycin (TOB), gentamicin (GEN),
89 nitrofurantoin (NIT), ciprofloxacin (CIP), piperacillin/tazobactam (TZP), amikacin (AMK),
90 ceftazidime (CAZ), levofloxacin (LVX), ceftazidime (CAZ), meropenem (MEM), imipenem

91 (IPM) and ertapenem (ETP) (CLSI, 2017). According to susceptibility results, strains were
92 classified as multidrug-resistant (MDR) and extensively drug-resistant (XDR).

93 For this work, MDR strains were defined as those strains which are resistant to the
94 therapeutic election categories (group A, CLSI 2018). XDR strains were classified as those
95 strains which are resistant to at least one agent in all or two therapeutic election categories
96 (group A and B, CLSI 2018). PDR strains were defined as those strains resistant to all
97 agents in all antimicrobial categories (group A, B, C and U, CLSI 2018) however colistin
98 was not taken for resistance classification because its associated with nephrotoxic damage
99 and it is not commonly used in clinical hospitals. Clinical isolates with resistance to one
100 antibiotic in less than three categories were considered as not classifiable.

101 **Confirmatory Extended-Spectrum β -lactamases by phenotype detection test**

102 ESBL confirmative test was performed using the Double Disc Synergy Test employing
103 ceftazidime (30 μ g), ceftazidime-clavulanate (30 μ g/10 μ g), cefotaxime (30 μ g), and
104 cefotaxime-clavulanate (30 μ g/10 μ g) disks. Quality control was done using *K. pneumoniae*
105 ATCC 700603 and *E. coli* ATCC 25922. \geq 5mm increase in diameter of ceftazidime-
106 clavulanate or cefotaxime-clavulanate indicates an ESLB producing microorganism
107 (positive result) (CLSI, 2018).

108 **Molecular characterization**

109 48 strains were selected to perform MLST scheme, strains selection was done considering
110 hospital unit, clinical sample origin, isolation year and results from susceptibility test. DNA
111 was extracted by guanidine thiocyanate method. Multilocus sequence typing scheme

112 (*gapA*, *infB*, *mdh*, *pgi*, *phoE*, *ropB* and *tonB*) has been described before by Diancourt (6).
113 DNA PCR products were purified by PureLink Quick gel extraction (ThermoFisher
114 Scientific, USA), PCR purification combo Kit (Invitrogen, USA) and EZ-10 Spin Column
115 PCR purification Kit (BioBasic, Canada). Sequencing PCR protocol was done using ABI
116 PRISM Big dye Termination v3.1 Cycle Sequencing Kits. ABIPRISM 3730XL equipment
117 was employed to read sequencing reactions.

118 **Sequence data analysis**

119 Blast alignment for each housekeeping gene was done to verify the sequence identity
120 (<http://www.ncbi.nlm.nih.gov/>). FinchTV v 1.4.0 (FinchTV 1.4.0 Geospiza), ClustalX v 2.1
121 (7) and Bioedit v 7.2.5 (8) programs were used to edit genes sequences. Finally, sequences
122 were submitted to *K. pneumoniae* PUBMLST web site ("<http://pubmlst.org/>") and gene
123 alleles and sequence type (ST) were assigned.

124 eBURST v3 program was used to obtain clonal complex (CC) (9). Sequence type analysis
125 was done with eBURST v3, START2 v 0.9.0, and DNAsp v5.10 program (10, 11).
126 ExPASy (www.expasy.org) web site was also used for amino acid translation.
127 Phylogenetic networks were constructed using START2 v 1.0.5
128 (<http://pubmlst.org/software/analysis/start2/>) program, *Neighbor-joining* method and
129 *balanced minimum evolution* (BME) criteria.

130 **Results**

131 ***K. pneumoniae* strains identification and susceptibility test**

132 Ninety-three *K. pneumoniae* strains were isolated from different clinical samples, the
133 49.5% (46/93) were isolated from urine, 21.5% (20/93) from blood, 9.7% (9/93) from
134 hospital surfaces, 8.6% (8/93) from catheter tip, 8.6% (8/93) from organic liquids and 5.4%
135 (5/93) from respiratory secretions.

136 Antimicrobial resistances obtained were as follows: AMP, 96% (89/93), CFZ, 61% (57/93),
137 SXT, 60% (56/93), SAM, 57% (53/93), FEP, 56% (52/93), CRO, 56% (52/93), TOB, 39%
138 (36/93), GEN, 35% (33/93), NIT, 27% (25/93), CIP, 22% (20/93), TZP, 16% (15/93),
139 AMK, 9% (8/93), MEM, ETP 2% (2/93) and IPMM, 1% (1/93). Sixty percent of the
140 population (56/93) were classified as ESBL producing strains by Vitek2®. The results were
141 confirmed by confirmatory test and they were matched with the Vitek2® results.
142 Classification resistance tests allowed us to distinguish 46% of the population (43/93) as
143 MDR strains, 17% (16/93) as XDR strains, and 1% (1/93) as PDR strains. 36% of the
144 population (33/93) were not classifiable.

145 **MLST results**

146 Phylogenetic analysis was performed with 48 strains and 2317 ST previously reported in
147 the MLST data base (<http://bigsd.b.pasteur.fr/>). In this study, 30 ST were identified :29 ST
148 corresponding to clinical strains and 1 ST from *K. pneumoniae* ATCC 700603 (table S1).

149 Burst algorithm identified groups of related genotypes (clonal complex) and allowed to
150 recognize the founding genotype of each group, though, analysis population snapshots were
151 obtained and showed a clonal structure [$I_A = 0.572$ (n=48) (START2 V.1.0.5)].

152 eBURST v3 program considers the 30 ST (including ATCC 700603 strain with ST489,
153 circled in green; and the clinical isolated strains, circled in red) that were identified in this

154 study with repetitions (1000 “bootstrap”). CC denomination was assigned according to
155 each group’s founding ST, and it is considered that a CC is composed by isolations that
156 have 6/7 identical loci. There was a total of 183 generated CC, the principal clonal complex
157 (CC11) is observed in the center of the “snapshots”, this complex showed 47 SLV, 43
158 DLV, 123 TLV and 688 SLV, in where 18 ST’s were found. Following CC to which the
159 isolated strains belong are: CC147 (ST885, ST392); CC628 (ST628); CC1088 (ST1088);
160 CC551 (ST551); CC2054 (ST10726); CC491 (ST491); CC405 (ST405) and CC307
161 (ST307). Individual ST’s (“singleton”) that were not part of a CC were ST2080, ST1846
162 and ST489. 23 ST’s (79%) were from 1 strain, 6 ST (21%) were from 2 or 6 isolates.
163 Predefined ST were ST551 and ST405 (12.5%, 6/48), then ST25 and ST1088 (8.3%), right
164 away ST392 (6.3%, 3/48%) and finally ST36 (4.1% 2/48). The six ST were considered the
165 clones prevalent in this study. MDR strains were ST25 (2/4), ST405 (2/6) (Fig. S1).

166 Isolations obtained were classified as follows: 46% (43/93) were MDR, 24 from Hospital I,
167 10 from Hospital II, 1 from Hospital III and 8 from hospital IV; 17% (16/93) were XDR, 10
168 from Hospital I, 1 from Hospital II, 2 and 3 from Hospital III and IV. PDR strain (1%,
169 1/93) was isolated form Hospital IV. ST392 (4/4), ST 1088 (3/3) and ST551 (3/6); XDR
170 strains were ST25 (2/4), ST551 (3/6) and ST405 (2/6); ST706 were PDR.

171 **Sequence Analysis:**

172 Characteristics and polymorphism of each gen are shown on Table S4*. Each gen number
173 of alleles varied from 4 (*gapA* y *rpoB*) to 17 (*tonB*), and the number of polymorphic sites
174 match with each gene mutations. Values of π , from 0.00463 (*pgi*) to 0.02794 (*gapA*) and θ

175 from 0.00364 (*gapA*) to 0.01331 (*rpoB*) were <1. G+C content was found over the 50% in
176 the seven genes, with ranges from 55.77% (*mdh*) to 64.66% (*tonB*).

177 Polymorphic changes match with the mutations, most of the “housekeeping” genes did not
178 show mutations on the different triplet positions, with synonymic and non-synonymic
179 amino acid changes. dn / ds relation for most genes were significantly <1, indicating that
180 there was not a strong selective pressure over the genes, thus why these genes do not affect
181 bacterial viability, excepting *infB* gene.

182 **Phylogenetical Relation**

183 Phylogenetical analysis was done with 48 isolated strains, following “*Neighbor-joining*”
184 method, based on BME (“*balanced minimum evolution*”) criteria, which determines the
185 closest sequences by binding them with an internal node at an 0.1 distance, repeating itself
186 on the remaining sequences until all of them are linked by those internal nodes, which
187 minimize each internal branch length, thus obtaining a phylogenetical tree in which its
188 branches length indicates de evolutive changes (Figure S3).

189 The phylogenetical tree shows an extern group, conformed by 10% (5/48) of isolated
190 strains, each with a different ST (ST846, ST491, ST111, ST804 y ST16), whereby,
191 phylogenetical distance varied. Internal group was divided into two different clads
192 (aggrupation with a common predecessor), A clad includes 50% (24/48) of the isolated
193 strains, while B clad includes 40% (19/48). Strains with the same ST (ST392, ST551,
194 ST36, ST1088, ST405, ST25) are found in the same clad and at the same distance. There
195 was no observed relation between antibiotic resistance with phylogenetical groups
196 formation.

197

198 **Discussion**

199 According with the CDC latest data, ESKAPE group bacteria are held responsible of two
200 thirds of all the Healthcare Associated Infections and play a significant role in worldwide
201 mortality. *Klebsiella pneumoniae* belongs to this groups. In Mexico, *Klebsiella pneumoniae*
202 is classified as one of the three principal HCAI etiologic agents, as well as the second most
203 reported microorganism in outbreaks. In the last 5 years, there has been an increase on the
204 number of cases. Though it is saprophytic bacterium found in gastrointestinal tract, skin,
205 nasopharynx, it can also cause community and hospital infections with a lethality rate of
206 35% (12).

207 In this study, ninety-three *K. pneumoniae* isolations, coming from 4 different hospitals
208 located on Mexico City were analyzed. The most frequent isolation source was urine
209 culture followed by blood culture. The RHOVE 2016 report emphasizes that *K.*
210 *pneumoniae* got second place in isolation frequency in bloodstream infections, and fourth
211 place in urinary system infections. There have been reports in other countries about high-
212 frequency isolations in blood and urinary system infections in third level hospitals contrary
213 to the reported by Shanmuga & Usha (2018) were bronchial secretion samples were found
214 in a low frequency.

215 On 2017, the WHO published for the first time the priority pathogen list, such pathogens
216 represent a public-health threat, considering the antibiotic resistance. Carbapenem resistant,
217 EEBL producer *K. pneumoniae* is included in “critical priority” (14).

218 Gashaw performed a study in a third level hospital, obtaining 30% MDR, 43% XDR and
219 7% PDR. β -lactam resistance is an increasing problem for the infection treatment, thereby,
220 use of carbapenem antibiotics for treatment of infections caused by EEBL producing
221 microorganisms was implemented. Nevertheless, carbapenem resistant strains have been
222 reported, elevating patients' mortality index (15).

223 Antibiotic resistance was determined in clinical isolated strains using Vitek2®, so
224 classification according to criteria described in this work, could be applied, obtaining a
225 higher MDR strains percentage (16) reported that 80% of a Mexico City hospital isolated
226 strains were MDR, nevertheless, no PDR strain was obtained, whereas in this study, one
227 PDR strain was found. This allows us to visualize the increasing resistance of *K.*
228 *pneumoniae* due to indiscriminate use of antibiotics for treatment of infection caused by
229 this bacterium. Resistance is associated with the expression of genes contained in plasmids,
230 transposons and integrones which are key elements in horizontal genetic material
231 transference. *Klebsiella* carbapenem resistance has been principally associated with
232 plasmids (15, 17).

233 On this work, MLST technique was applied for the establishment of a genetic relation on
234 clinical isolated strains associated to outbreaks of *K. pneumoniae*. 48 isolations were
235 analyzed, beside a control strain of *K. pneumoniae* ATCC 700603 used for validation,
236 obtaining ST489 for such strain (18). On the clinical isolated strain analysis, 29 type
237 sequences were obtained and none of the new alleles contained on the PubMLST database.
238 23 ST matched to one strain, and the six remaining strains were considered as clones
239 (ST551, ST405, ST25, ST1088, ST392, ST36). Diverse clones had been previously

240 reported on distant countries from Mexico, which allows us to visualize the rapid
241 dissemination of some clones.

242 Index association was done for the present clones in this study, allowing to confirm with
243 eBRUST algorithm that the studied population was clonal type, in other words, the isolated
244 strains are genetically related.

245 “Neighbor-joining” method was used for the construction of a phylogenetical tree and for a
246 better visualization of the phylogeny analysis. The analysis showed two principal clads.
247 The A clad contains 50% of the isolations coming from the 4 mentioned hospitals, of these,
248 13 were classified as MDR, 5 as XDR and 1 as PDR. Predominant ST’s for this clad were:
249 **ST551**, isolated on 2012 from hospital I and from hospital II on 2013 from patients and
250 surface samples. This strain was held responsible for an outbreak on Azcapotzalco
251 delegation on Mexico City. This clone was also isolated on years 2011 – 2013 in Japan,
252 according to (19), where its major isolation frequencies were in urine and respiratory
253 secretion samples.

254 **ST392** was found on hospital IV on 2015, this strain was classified as endemic for the
255 hospital. **ST392**, was detected during an 11-month survey; also, **ST307** (20), reported as
256 well in Italy (21), where they mention that this clone is highly risky due to its rapid
257 dissemination, plus the characterized isolations of this strain were KPC producers. This
258 specific clone has been reported in Korea, Pakistan, Italy, Morocco, Mexico, Serbia and
259 Japan. Because it’s been reported in different countries worldwide, this clone is a strong
260 candidate to become a high-risk clone in a near future.

261 **ST36** was isolated from hospital I on 2015 and from hospital II on 2013; all isolations were
262 susceptible to previously mentioned antibiotics, meaning an advantage for the patient's
263 treatment, because the bacteria can be dealt with following the medical instructions, surface
264 sanitization and adequate treatment. Nevertheless, on countries like China, this same clone
265 has been reported as a hyper virulent strain with carbapenem resistance (22). **ST706** was
266 the only PDR strain, and was isolated from hospital IV on 2015. There are no current
267 published papers about this strain.

268 B clad contains 39.6% of the isolations, 10 were classified as MDR and 4 as XDR,
269 according to the classification. Predominant ST's in this clad were: **ST405** in hospital I,
270 correspondent to years 2011, 2012 and 2015; in hospital II on 2013 and in hospital IV in
271 2015. Its most frequent isolation sources were urine and blood culture.

272 **ST405** clone was responsible for outbreaks in Spain in years 2010-2012, nevertheless, it
273 was disseminated time after that to countries like Italy, where it caused an outbreak on
274 years 2013 – 2014, later to Austria and Germany. Studies performed on 2019 mention that,
275 unlike the isolations obtained in Spain, these isolations did not present OXA-84 (23).
276 Nevertheless, they presented other virulence factors. This was attributed to the fact that
277 most of the samples obtained were taken from water bodies near the hospitals, better said,
278 community waters. These strains have proved susceptible to antibiotics, while hospital
279 strains are resistant, but wild strains express more virulence factors.

280 **ST25** clone was found in hospitals I and IV on 2015, and in hospital II on 2013. This clone
281 was isolated in Japan on 2008, and in China on the June 2014-May 2015 period. ST1088
282 was found only on inert surfaces in hospital II on 2013 and was classified as endemic for

283 such hospital. This suggests that no adequate survey or preventive measures for this
284 bacterium have been taken, that is why it is important to rotate the disinfecting solutions
285 every once in a while.

286 These ST's present major importance since they're present in at least three hospitals located
287 in different areas inside Mexico City.

288 ST258 is one of the most widely disseminated and most prevalent clones, there are several
289 reports about this clone presenting resistance to multiple pharmaceuticals, including
290 carbapenems. Nevertheless, this clone was not found in this study. There have been reports
291 about carbapenem resistance associated clones in Brazil and China, such as ST11, ST25
292 and ST392. These clones were obtained in this study but showed sensibility to these
293 antibiotics. However, precaution must be taken because these strains can easily obtain
294 genetic material for carbapenem resistance.

295 ST's reported in this study had been previously reported in other countries' outbreaks,
296 except **ST706** and **ST1088**, however, in Mexico, not all the reported clones were well
297 described. That's why it is important to emphasize the importance of the survey, since
298 great part of them were classified as MDR. This allows us to evaluate the status of *K.*
299 *pneumoniae* caused infections in Mexico by comparing it with previously published
300 studies, observing the increase in resistance and dissemination of diverse clones that were
301 reported in other countries.

302 **Acknowledgments**

303 This work's authors thank Dr. Laura López Pelcastre and C. Carmen Melchor Díaz, as well
304 as the Mexican Institute for the Social Security for their input into this project.

305 **References**

306 1. Vargas L. 2010. *K. pneumoniae*: ¿la nueva “superbacteria”? Patogenicidad,
307 epidemiología y mecanismos de resistencia. Revista Médica Universidad de Antioquia.
308 23:157-165.

309 2. Bialek-Davenet S, Criscuolo A, Passet V, Jones L, Delannoy-Vieillard AS, Garin B, Le
310 Hello S, Arlet G, Nicolas-Chanoine MH, Decré D, and Brisse S. 2014. Genomic definition
311 of hypervirulent and multidrug-resistant *Klebsiella pneumoniae* clonal groups. Emerg Infect
312 Dis. 20:1812-1820.

313 3. Vera LA., Barría LC., Carrasco AS., Lima C., Aguayo RA., Dominguez M., Bello TH.,
314 González RG. 2017. KPC: *Klebsiella pneumoniae* carbapenemasa, principal
315 carbapenemasa en enterobacterias. Rev Chilena Infectol. 34(5);476-484.

316 4. Wang Q, Li B, Tsang AK, Yi Y, Woo PC, and Liu CH. 2013. Genotypic analysis of
317 *Klebsiella pneumoniae* isolates in a Beijing hospital reveals high genetic diversity and
318 clonal population structure of drug-resistant isolates. PloS one. 8:e57091.

319 5. Gomez SA and Uhlemann AC. 2017. Clinical implications of genomic adaptation and
320 evolution of Carbapenem-resistant *Klebsiella pneumoniae*. J. Infect Dis. 215:S18-S27.

- 321 6. Diancourt L, Passet V, Verhoef J, Grimont PA, and Brisse S. 2005. Multilocus sequence
322 typing of *Klebsiella pneumoniae* nosocomial isolates. *Journal of Clinical microbiology*.
323 43:4178-4182.
- 324 7. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam
325 H, Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, and Higgins D.
326 2007. Clustal W and Clustal X version 2.0. *Bioinformatics*. 23:2947-8.
- 327 8. Hall T. 1999. BioEdit: a user-friendly biological sequence alignment editor and analysis
328 program for Windows 95/98/NT. *Nucleic Acids Symposium*. 41:95-98.
- 329 9. Feil EJ, Li BC, Aanensen DM, Hanage WP, and Spratt BG. 2004. eBURST: inferring
330 patterns of evolutionary descent among clusters of related bacterial genotypes from
331 multilocus sequence typing data. *Journal of Bacteriology*; 186:1518-30.
- 332 10. Jolley KA, Feil EJ, Chan MS, Maiden MC. 2001. Sequence type analysis and
333 recombinational tests (START). *Bioinformatics*.17:1230-1.
- 334 11. Librado P and Rozas J. 2009. DnaSP v5: A software for comprehensive analysis of
335 DNA polymorphism data. *Bioinformatics*. 25:1451-1452.
- 336 12. RHOVE. (2015). *Informe anual 2015*. México: DGE.
- 337 13. Shanmuga V, Usha B. 2018. ESKAPE pathogens: Trends in antibiotic resistance
338 pattern. *International Journal of Microbiology* 7(3):26-32.

- 339 14. OMS. (30 de abril de 2014). *El primer informe mundial de la OMS sobre la resistencia*
340 *a los antibióticos pone de manifiesto una grave amenaza para la salud pública en todo el*
341 *mundo*. Recuperado el 1 de febrero de 2016, de Organización Mundial de la Salud:
342 www.who.int/mediacentre/new/releases/2014/amr-report/es/
- 343 15. Gashaw M, Berhane M, Bekele S, Kibru G, Teshager L, Yilma Y, Ahmed Y, Fentahun
344 N, Assefa H, Wieser A, Gudina EK, Ali S. 2018. Emergence of high drug resistant bacterial
345 isolates from patients with health care associated infections at Jimma University medical
346 center: a cross sectional study. *Antimicrobial Resistance & Infection Control* [Internet].
347 7(1).
- 348 16. Ostría-Hernández ML, Juárez- de la Rosa KC, Arzate-Barbosa P, Lara-Hernández A,
349 Sakai F, Ibarra JA, Gastro-Escarpulli, Vidal JE. 2018. Nosocomial, Multidrug-Resistant
350 *Klebsiella pneumoniae* strains isolated from Mexico City produce Robust Biofilms on
351 abiotic surfaces but not on Human Lung Cells. *Microb Drug Resist.* 24(4): 422-433.
- 352 17. Guzmán M., Alonso G. 2010. Characterization of the variable region within class 1
353 integrons in *Klebsiella pneumoniae* nosocomials strain. *Revista médica de Chile* v.138 n.3.
- 354 18. Wang Q, Li B, Tsang AKL, Yi Y, Woo PCY, Liu CH. 2013. Genotypic analysis of
355 *Klebsiella pneumoniae* isolates in a Beijing Hospital Reveals High Genetic Diversity and
356 clonal population structure of drug-resistant isolates. *PLoS ONE* 8(2): e57091.
- 357 19. Higashino M, Murata M, Morinaga Y, Akamatsu N, Matsuda J, Takeda K, Kaku N,
358 Kosai K, Uno N, Hasegawa H, Yanagihara. 2017. Fluoroquinolone resistance in extended-
359 spectrum β -lactamase-producing *Klebsiella pneumoniae* in a Japanese tertiary hospital:

360 silent shifting to CTX-M-15-producing *K. pneumoniae*. *Journal of Medical Microbiology*.
361 66(10):1476-82.

362 20. Bocanegra-Ibarias P, Garza-González E, Morfín-Otero R, Barrios H, Villarreal-Treviño
363 L, Rodríguez-Noriega E, Garza-Ramos U, Petersen-Morfin S, Silva-Sanchez J. 2017.
364 Molecular and microbiological report of a hospital outbreak of NDM-1-carrying
365 Enterobacteriaceae in Mexico. *PLOS ONE*. 12(6):e0179651..


366 21. Villa L, Feudi C, Fortini D, Brisse S, Passet V, Bonura C, Endimiani A, Mammina C,
367 Ocampo AM, Jimenez JN, Doumith M, Woodford N, Hopkins K, Carattoli A. 2017.
368 Diversity, virulence, and antimicrobial resistance of the KPC-producing *Klebsiella*
369 *pneumoniae* ST307 clone. *Microbial Genomics* [Internet]. 3(4).

370 22. Feng Y, Lu Y, Yao Z, Zong Z. 2018. Carbapenem-Resistant Hypervirulent *Klebsiella*
371 *pneumoniae* of Sequence Type 36. *Antimicrobial Agents and Chemotherapy* [Internet].
372 62(7).

373 23. Lepuschitz S, Schill S, Stoeger A, Pekard-Amenitsch S, Huhulescu S, Inreiter N, Harti
374 R, Kerschner H, Sorschag S, Springer B, Brisse S, Allerberger F, Mach RL, Ruppitsch W.
375 2019. Whole genome sequencing reveals resemblance between ESBL-producing and
376 carbapenem resistant *Klebsiella pneumoniae* isolates from Austrian rivers and clinical
377 isolates from hospitals. *Science of The Total Environment*. 662:227-35.

378

379



380 **FIG S1. Snapshot from *K. pneumoniae*, comparative analysis eBURST. 48 ST from**
381 *K.pneumoniae* were identified (red circle); *K. pneumoniae* ATCC 700603 (green circle);
382 founders were in the center of each clonal complex. Individual ST were highlighted with a
383 a line.

384

385


386 **Table S2** Allelic form gene and ST assignment from clinical and reference strains

Hospital	Year	Strain	Allelic profile							*ST
			<i>gapA</i>	<i>rpoB</i>	<i>mdh</i>	<i>pgi</i>	<i>phoE</i>	<i>infB</i>	<i>tonB</i>	
ATCC 700603			18	52	26	71	98	22	51	489
HOSPITAL I	2011	1E	2	1	1	3	8	1	15	2015
		2E	2	1	62	3	10	4	110	405
		3E	2	1	1	1	9	4	12	23
		4E	2	1	1	6	7	4	12	496
		5E	2	1	62	3	10	4	110	405
		6E	2	1	164	1	7	4	303	1846
	2012	7E	2	9	2	1	13	1	10	309
		8E	3	1	1	1	9	4	135	551
		9E	3	1	1	1	9	4	135	551
		10E	3	1	1	1	9	4	135	551
		11E	2	1	62	3	10	4	110	405
		12E	3	1	1	1	9	4	135	551
		13E	51	1	5	1	9	4	13	491
	2015	14E	2	1	62	3	10	4	110	405
		15E	2	1	1	1	10	4	13	25
		16E	2	1	5	1	17	4	42	111
		17E	2	1	1	1	7	1	12	485
		18E	2	1	2	1	4	4	4	16
		19E	2	1	2	1	7	1	7	36
		20E	2	60	11	1	4	8	24	628
		21E	2	1	2	1	1	4	13	804
		22E	2	1	1	117	10	4	18	1726
		23E	2	1	1	1	10	4	13	25
		24E	3	3	1	1	9	1	4	1869
		25E	2	9	2	1	13	1	16	37
Hospital II	2013	1S	2	1	1	10	1	1	76	1088
		2S	2	1	1	10	1	1	76	1088
		3S	3	1	1	1	9	4	135	551
		4S	2	1	1	10	1	1	76	1088
		5S	2	1	2	1	213	1	7	2175
		6S	2	1	1	10	1	1	76	1088
		7S	3	1	1	1	9	4	135	551
		8S	2	1	162	3	10	4	110	405
Hospital III	2013	1I	2	4	2	1	7	1	12	788
		2I	3	3	1	1	13	1	79	1406
		3I	2	1	1	1	10	4	13	25
		4I	2	1	97	1	9	4	13	846
		5I	2	1	2	1	7	1	7	36
HOSPITAL IV	2015	1Z	2	1	1	1	10	4	13	25
		2Z	2	1	62	3	10	4	110	405
		3Z	4	1	2	52	1	1	7	307
		4Z	3	4	6	1	7	4	40	392
		5Z	4	1	32	1	7	4	10	151
		6Z	3	4	6	1	7	4	40	392
		7Z	4	5	88	1	1	94	23	2080
		8Z	3	4	6	1	7	4	13	885
		9Z	2	4	1	1	7	4	4	706
10Z	3	4	6	1	7	4	40	392		

387 *ST Sequence type. E: Hospital I, S, Hospital II; I: Hospital III, and Z: Hospital IV.

388

389



390 **FIG S3. Phylogenetic tree from clinical samples of *K. pneumoniae* strains obtained**
 391 **by Neighbor-joining method, through the START v.0.9.0 program.** The length of the
 392 branches of the phylogenetic tree indicate the evolutionary change of each isolate. A and
 393 B form the intern group, each one them represent a clade and subdivide on subclades. C
 394 is a extern group.

395

Table S4. Characteristics and polymorphism of the *housekeeping* genes from *K. pneumoniae* isolated.

Gene	PCR product size	Haplotype	Polymorphic sites	Total mutations	π^*	θ^*	G+C	dN*	dS*	dN/dS
<i>gapA</i>	450	4	3	3	0.02794	0.00364	0.5615	0.0000	0.0132	0.0000
<i>infB</i>	318	6	7	7	0.00797	0.00964	0.6140	0.0097	0.0037	2.6548
<i>mdh</i>	477	10	21	21	0.00526	0.00684	0.5577	0.0086	0.0145	0.5944
<i>pgi</i>	432	6	6	6	0.00463	0.00608	0.5733	0.0042	0.0056	0.7531
<i>phoE</i>	420	9	9	9	0.00728	0.00788	0.5585	0.0000	0.0311	0.0000
<i>rpoB</i>	501	4	13	13	0.01331	0.01331	0.5415	0.0128	0.0147	0.8713
<i>tonB</i>	414	17	16	16	0.01027	0.01143	0.6466	0.0050	0.0257	0.1961

396 π^* : Nucleotide diversity per site.
 397 θ^* : Average of nucleotide differences per site.
 398 dN*: Numbers of non-synonymous substitutions per site.
 399 dS*: Numbers of synonymous substitutions per site.

400

401

402

403

404

405

406

407